克服固体瘤细胞免疫疗法的功能和转化挑战
Yi-Ching Chen1, Kok-Siong Chen1, Bruce L Levine2
1Center for Stem Cell and Translational Immunotherapy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Cancer cell
|February 27, 2026
概括
基于细胞的免疫疗法对癌症治疗有希望,但在固体瘤中面临重大障碍. 本综述探讨了针对固体瘤的这些疗法的发展所面临的挑战和解决方案.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 生物技术是生物技术.
背景情况:
- 免疫疗法,特别是基于细胞的疗法,已经改变了癌症治疗.
- 细胞疗法如工程T细胞,NK细胞,干细胞和疫苗利用免疫细胞向癌症.
- 虽然在血液癌症中有效,但细胞疗法在治疗固体瘤方面面临挑战.
研究的目的:
- 审查阻碍对固体瘤进行自身细胞和异性细胞基癌症疗法的临床转化的主要挑战.
- 确定影响这些疗法的疗效和发展的功能和转化障碍.
- 探索下一代细胞免疫疗法的潜在解决方案和未来方向.
主要方法:
- 关于基于细胞的癌症疗法的当前研究的文献综述.
- 分析固体瘤微环境中的功能限制.
- 在临床开发和实施中对转化障碍的评估.
主要成果:
- 显著的功能挑战限制了固体瘤的治疗疗效.
- 翻译方面的挑战阻碍了细胞疗法的临床开发和广泛应用.
- 现有的细胞疗法在固体瘤治疗方面表现出有限的成功,与血液恶性瘤相比.
结论:
- 克服固体瘤的障碍需要创新的工程策略和组合方法.
- 新兴技术对于开发下一代细胞免疫疗法至关重要.
- 解决功能和转化方面的挑战对于在固体瘤中获得更广泛的临床成功至关重要.
相关概念视频
Tumor Immunotherapy
2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Cancer Vaccines
1.2K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.2K
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Cytotoxic T Cells-mediated Immune Response
7.7K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.7K
Cell-mediated Immune Responses
85.1K
Overview
85.1K


